Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: a phase 3 open-label study

H Lv, S Wang, Z Liang, W Yu, C Yan, Y Chen, X Hu… - Vaccine, 2022 - Elsevier
Background The 9-valent human papillomavirus (9vHPV; HPV6/11/16/18/31/33/45/52/58)
vaccine was approved for use in Chinese women aged 16–26 years in 2018. This phase 3 …
被引用次数：11 相关文章

Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: a phase 3 open-label study.

H Lv, S Wang, Z Liang, W Yu, C Yan, Y Chen, X Hu… - 2022 - cabidigitallibrary.org
Background: The 9-valent human papillomavirus (9vHPV; HPV6/11/16/18/31/33/45/52/58)
vaccine was approved for use in Chinese women aged 16-26 years in 2018. This phase 3 …

Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study.

H Lv, S Wang, Z Liang, W Yu, C Yan, Y Chen, X Hu… - Vaccine, 2022 - europepmc.org
Background The 9-valent human papillomavirus (9vHPV; HPV6/11/16/18/31/33/45/52/58)
vaccine was approved for use in Chinese women aged 16-26 years in 2018. This phase 3 …

Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study

H Lv, S Wang, Z Liang, W Yu, C Yan, Y Chen… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The 9-valent human papillomavirus (9vHPV; HPV6/11/16/18/31/33/45/52/58)
vaccine was approved for use in Chinese women aged 16-26 years in 2018. This phase 3 …

Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study.

H Lv, S Wang, Z Liang, W Yu, C Yan, Y Chen, X Hu… - Vaccine, 2022 - europepmc.org
Background The 9-valent human papillomavirus (9vHPV; HPV6/11/16/18/31/33/45/52/58)
vaccine was approved for use in Chinese women aged 16-26 years in 2018. This phase 3 …

[引用][C] Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: A phase 3 open-label study

H Lv, S Wang, Z Liang, W Yu, C Yan, Y Chen, X Hu… - 2022